Anacor Pharmaceuticals, which is developing novel small-molecule therapeutics derived from its boron chemistry platform, filed on Friday with the SEC to raise up to $86 million in an initial public offering. The Palo Alto, CA-based company, which was founded in 2000 as AnaMax, Inc. and booked $15 million in sales for the 12 months ended June 30, plans to list on the NASDAQ under the symbol ANAC. Citi and Deutsche Bank Securities are the lead underwriters on the deal, for which pricing terms and timing were not disclosed. Anacor Pharmaceuticals previously filed an S-1 in August 2007 before withdrawing the deal in December of the following year.
